Browse > Article

Visceral Pleural Invasion as a Prognostic Factor for Recurrence in Resected IB Non-small Cell Lung Cancer  

Kim, Seok (Department of Thoracic and Cardiovascular Surgery, Daegu Catholic Medical Center)
Park, Ki-Sung (Department of Thoracic and Cardiovascular Surgery, Daegu Catholic Medical Center)
Kum, Yoon-Seup (Department of Pathology, Daegu Catholic Medical Center)
Lee, Sub (Department of Thoracic and Cardiovascular Surgery, Daegu Catholic Medical Center)
Bae, Chi-Hoon (Department of Thoracic and Cardiovascular Surgery, Daegu Catholic Medical Center)
Hyun, Dae-Sung (Department of Internal Medicine, Daegu Catholic Medical Center)
Publication Information
Journal of Chest Surgery / v.42, no.5, 2009 , pp. 610-614 More about this Journal
Abstract
Background: Several trials have reported on whether adjuvant chemotherapy for resected stage IB non-small cell lung cancer is needed. The aim of our study was to investigate prognostic factors for recurrence to help identify patients who should receive adjuvant chemotherapy. Material and Method: We reviewed the cases of 48 stage IB non-small cell lung cancer patients between 1997 and 2006. Disease-free survival and overall survival rates were calculated by the Kaplan-Meier method. Univariate analysis was performed with the log rank test and multivariate analysis was done using Cox's proportional hazard model. Result: The median follow-up time was 48 months. The overall survival rate was 55.9%, and the disease-free survival rate was 48.6%. Of 8 variables, two factors, visceral pleural invasion and Iymphovascular invasion, were prognostic factors of disease-free survival (univariate analysis). Visceral pleural invasion was a significant prognostic factor in multivariate analysis, and overall survival in com-pared one or more variable such as visceral pleural invasion or, and lymphovascular invasion with the other variables. Conclusion: Visceral pleural invasion was identified as a poor prognostic factor and it may help select which patients will benefit from adjuvant chemotherapy in addition to more comprehensive follow-up.
Keywords
Neoplasm stage; Adjuvant therapy; Visceral pleural invasion;
Citations & Related Records
연도 인용수 순위
  • Reference
1 International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-60   DOI   ScienceOn
2 Strauss GMH, Maddaus JE, Johnstone MA, et al. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): update of cancer and leukemia group B (CALGB) protocol 9633. J Clin Oncol 2006;24(suppl):7007
3 Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst 2003; 95:1453-61   DOI
4 Kurokawa T, Matsuno Y, Noguchi M, Mizuno S, Shimosato Y. Surgically curable "early" adenocarcinoma in the periphery of the lung. Am J Surg Pathol 1994;18:431-8   DOI
5 Padilla J, Calvo V, Penalver JC, et al. Survival and risk model for stage IB non-small cell lung cancer. Lung Cancer 2002;36:43-8   DOI   ScienceOn
6 Thomas PA, Piantadosi S, and the Lung Cancer Study Group. Postoperative T1N0 non-small cell lung cancer. Squamous versus non-squamous recurrence. J Thorac Cardiovasc Surg 1987;94:349-54
7 Suzuki K, Nagai K, Yoshida J, et al. Conventional clinicopathologic prognostic factors in surgically resected nonsmall cell lung carcinoma. Cancer 1999;86:1976-84   DOI   ScienceOn
8 Harpole DH Jr, Herndon JE 2nd, Young WG Jr, et al. Stage I nonsmall cell lung cancer: a multivariate analysis of treatment methods and patterns of recurrence. Cancer 1995;76: 787-96   DOI   ScienceOn
9 Sawyer TE, Bonner JA, Gould PM, et al. Patients with stage I non-small cell lung carcinoma at postoperative risk for local recurrence, distant metastasis, and death: implications related to the design of clinical trials. Int J Radiat Oncol Biol Phys 1999;45:315-21
10 Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111:1710-7   DOI   PUBMED   ScienceOn
11 Manac’h D, Riquet M, Medioni J, et al. Visceral pleura invasion by non-small cell lung cancer: an underrated bad prognostic factor. Ann Thorac Surg 2001;71:1088-93   DOI   ScienceOn
12 Ravdin PM, Davis G. Prognosis of patients with resected non-small cell lung cancer: impact of clinical and pathologic variables. Lung Cancer 2006;52:207-12   DOI   ScienceOn
13 Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-97   DOI   ScienceOn
14 Shimizu K, Yoshida J, Nagai K, et al. Visceral pleural invasion is as invasive and aggressive indicator of non-small cell lung cancer. J Thorac Cardiovasc Surg 2005;130:160-5   DOI   ScienceOn
15 Read RC, Yoder G, Schafer RC. Survival after conservative resection for T1N0M0 non-small cell lung cancer. Ann Thorac Surg 1990;49:349-54
16 Goya T, Asamura H, Yoshimura H, et al. Prognosis of 6644 resected non-small cell lung cancers in Japan. A Japanese lung cancer registry study. Lung Cancer 2005;50:227-34   DOI   ScienceOn
17 Martini N, Bains MS, Burt ME, et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg 1995;109:120-9   DOI   ScienceOn